Head-To-Head Review: PDL BioPharma (NASDAQ:PDLI) vs. Organovo (NASDAQ:ONVO)

PDL BioPharma (NASDAQ:PDLI) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Volatility & Risk

PDL BioPharma has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Organovo has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500.

Institutional and Insider Ownership

96.5% of PDL BioPharma shares are held by institutional investors. Comparatively, 43.0% of Organovo shares are held by institutional investors. 2.3% of PDL BioPharma shares are held by insiders. Comparatively, 3.5% of Organovo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares PDL BioPharma and Organovo’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PDL BioPharma -32.13% 6.86% 5.17%
Organovo -861.70% -70.01% -63.41%

Valuation & Earnings

This table compares PDL BioPharma and Organovo’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PDL BioPharma $198.11 million 1.80 -$68.86 million $0.37 8.05
Organovo $3.09 million 19.34 -$26.64 million ($0.23) -2.17

Organovo has lower revenue, but higher earnings than PDL BioPharma. Organovo is trading at a lower price-to-earnings ratio than PDL BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PDL BioPharma and Organovo, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PDL BioPharma 0 1 0 0 2.00
Organovo 0 0 2 0 3.00

PDL BioPharma presently has a consensus target price of $3.00, suggesting a potential upside of 0.67%. Organovo has a consensus target price of $2.13, suggesting a potential upside of 325.00%. Given Organovo’s stronger consensus rating and higher probable upside, analysts clearly believe Organovo is more favorable than PDL BioPharma.

PDL BioPharma Company Profile

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures, markets, and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Organovo Company Profile

Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.